Change in Binding Reactivity of an Anti-Tumor Monoclonal Antibody After the Introduction of 2-Pyridyl Disulphide Groups
- 1 January 1986
- journal article
- research article
- Published by Mary Ann Liebert Inc in Hybridoma
- Vol. 5 (1) , 1-8
- https://doi.org/10.1089/hyb.1986.5.1
Abstract
The use of monoclonal antibodies for in vivo therapeutic approaches depends largely on their specificity. During the characterization of ricin A-chain-murine monoclonal antibody conjugates we found that the binding specificity of a monoclonal antibody raised against human ovarian carcinoma (MOv2) seemed altered. Therefore, the binding reactivity of the unmodified antibody (MOv2), the conjugation intermediate (MOv2-PDP) and the conjugate (MOv2-A chain) was titrated by solid-phase radioimmunoassay on 11 human tumor cell lines belonging to seven different histotypes. The three reagents bound with the two reference cell lines (SW626:ovary carcinoma and HT-29:colon carcinoma). The MOv2-PDP and the Mov2-A chain also reacted with seven other cell lines which were unreactive with the unmodified MOv2. In addition MOv2-PDP exhibited reactivity on all normal cells tested (peripheral blood lymphocytes and skin fibroblasts). To elucidate the significance of these findings the following experiments were performed: cross inhibitions between the unmodified and modified monoclonal antibodies; comparative absorption tests with different cell lines; and immunoblotting analysis of the target antigens. The results suggest that after chemical modification with SPDP the monoclonal antibody MOv2 increases its binding activity, so that even a low number of antigenic sites can be detected. This study underlines the need to redefine the specificity of a conjugate before considering therapeutic applications.Keywords
This publication has 14 references indexed in Scilit:
- Monoclonal antibodies in cancer therapy.Journal of Clinical Oncology, 1983
- Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth.Proceedings of the National Academy of Sciences, 1983
- Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma‐associated antigen p97International Journal of Cancer, 1982
- Selective killing of malignant cells in a leukaemic rat bone marrow using an antibody–ricin conjugateNature, 1982
- In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins.The Journal of Experimental Medicine, 1982
- Specific killing of a human breast carcinoma cell line by a monoclonal antibody coupled to the A-chain of ricinCancer Immunology, Immunotherapy, 1981
- Anti-transferrin receptor monoclonal antibody and toxin–antibody conjugates affect growth of human tumour cellsNature, 1981
- Anti-Thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific toxin.Proceedings of the National Academy of Sciences, 1980
- Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells.Proceedings of the National Academy of Sciences, 1980
- Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagentBiochemical Journal, 1978